Rapid-Acting Insulin Dose
PreclinicalSmall molecule
Rapid-Acting Insulin Dose is one of 3 small molecule programs targeting T1DM. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
3 competitors in T1DM
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaPhase 3
Ozempic
Novo NordiskPhase 3
Rapid-Acting Insulin Dose
NNorthumbria University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rapid-Acting Insulin Dose. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- NNorthumbria University